IL-7

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

Retrieved on: 
Monday, April 4, 2022
Company, IL-7, Cancer, Cytokine, Mnemos EP, Heart, Lymphocyte, TME, Immunotherapy, Memory, Tumor microenvironment, AACR, Frontiers, PD-1, ISIN, OSE, GLOBE, Interleukin 7, Patient, Vaccine, Immunology

NANTES, France, April 04, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company is invited to present the latest progress on its bispecific antibody checkpoint inhibitor BiCKI® platform, and in particular on its bifunctional therapy targeting PD-1 and the Interleukin-7 (IL-7) cytokine, BiCKI®-IL-7, during a plenary oral presentation in an educational session dedicated to immunocytokines at the American Association Cancer for Research (AACR) annual meeting to be held on April 8 – 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • This immunotherapy has potential to address the high medical need of patients with cancers with primary or secondary resistance (1) or that are refractory to immune checkpoint inhibitor treatments.
  • In parallel to the ongoing late-stage preclinical testing, the industrial development of BiCKI-IL-7 has been recently initiated, representing another critical step in the products development.
  • The BiCKI platform, and in particular the bifunctional therapy BiCKI-IL-7v, preferentially delivers the IL-7 cytokine at the heart of the tumor microenvironment (TME) where T PD1+ lymphocytes accumulate in response to immunotherapy.
  • Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics comments: We are very proud to share an update on the advancements made with our preclinical immunology product, BiCKI-IL-7, in an oral session dedicated to an overview of the novel trends in cytokine immunotherapy.

OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment

Retrieved on: 
Monday, March 21, 2022
IL-7, Mnemos EP, United States Patent and Trademark Office, Epitope, Inflammation, Degenerative disease, Partnership, Patent, Ligand, Cancer, Transplant, Immunotherapy, PD-L2, Clinical trial, IND, Tumor microenvironment, Ulcerative colitis, Mab, Fortification, USPTO, Tissue, PD-1, Autoimmune disease, ISIN, Immune system, Boehringer Ingelheim, OSE, COVID-19, GLOBE, Nivolumab, PD-L1, Patient, Pancreatic cancer, Large-cell lung carcinoma, Fine chemical, Pharmaceutical industry, Vaccine

This patent will strengthen the global intellectual property of OSE-279 and will provide the product protection until 2039.

Key Points: 
  • This patent will strengthen the global intellectual property of OSE-279 and will provide the product protection until 2039.
  • OSE-279 is a humanized anti-PD1 monoclonal antibody blocking PD-L1 and PD-L2, the ligands of PD1 overexpressed by tumor cells.
  • Upregulation of PD-L1 and PD-L2 on tumor cells and other cell types of the tumor microenvironment is a proposed mechanism of tumor immune escape.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

Retrieved on: 
Wednesday, March 16, 2022
Â, Immunotherapy, OSE, Peptide, GLOBE, Patient, Immunity, Membrane protein, SARS, Fortification, Partnership, Immunodeficiency, Therapy, Boehringer Ingelheim, MERS, COVID-19, Large-cell lung carcinoma, Epitope, Capsid, Degenerative disease, Transplant, Week, IND, CD8, Clinical trial, Pancreatic cancer, ISIN, Cancer, Tissue, Severe acute respiratory syndrome coronavirus 2, Mnemos EP, Mab, Inflammation, Lung, PD-1, Nivolumab, Immune system, Longevity, Variants of SARS-CoV-2, IL-7, Coronavirus, Autoimmune disease, Ulcerative colitis, T cell, Vaccine, Pharmaceutical industry, Omicron, Delta

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.

Key Points: 
  • Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.
  • NANTES, France, March 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announces positive analysis of the long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19, with positive immunological results obtained at 6 months on T cell memory response in the vaccinated subjects.
  • This long term positive immune response is of strong interest (2) as more multispecific memory T cells are expected to be efficient for immunocompromised patients in case of any new emerging coronavirus or variants of concern.
  • In preclinical testing, CoVepiT demonstrated the ability to activate T cell defenses through CD8 T-cell multi-epitope responses for long-term T memory cell immunity.

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

Retrieved on: 
Monday, March 14, 2022
Lung, International, BLA, ORR, U.S. Securities and Exchange Commission, Survival, CTOS, Conference call, Private Securities Litigation Reform Act, Synovial sarcoma, Genentech, SPEAR, PSLRA, Review, Disease, Program, Company, ESMO, Ovarian cancer, GLOBE, Patient, IL-7, CCIT, CTA, Cancer, Neoplasm, SEC, R, Head, EDT, TIL, IND, Research, Annual report, Hlas, Astellas Pharma, Conference, Navy Yard, CCL19, TILS, Sale, Security (finance), Center, TCR, ADAP, Nasdaq, HIT Entertainment, The Independent Review, ADP, EGJ, Neck, G&A, Engineering, Birth control, Pharmaceutical industry, 3D printing, Medical device, Vaccine, Cryptocurrency

SPEARHEAD-1 met its primary endpoint and we identified further indications for late-stage development with our next-gen SPEAR T-cells targeting MAGE-A4.

Key Points: 
  • SPEARHEAD-1 met its primary endpoint and we identified further indications for late-stage development with our next-gen SPEAR T-cells targeting MAGE-A4.
  • Revenue: Revenue for the fourth quarter and year ended December 31, 2021 was $1.4 million and $6.1 million, respectively, compared to $1.5 million and $4.0 million for the same periods in 2020.
  • Revenue for the year ended December 31, 2021 has increased primarily due to an increase in development activities under our collaboration arrangements.
  • After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (1343635).

NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, March 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Amgen, Industry, GSK, AACR, NIT, American Association for Cancer Research, Novartis, Company, Cancer, Infection, BMS, IL-7, American Association, KOSDAQ, PricewaterhouseCoopers, Immunity, Association, Eli Lilly, Pharmaceutical industry, Pfizer, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, announced today that new preclinical data for the companys lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Association for Cancer Research (AACR) annual meeting, to be held in New Orleans on April 8-13, 2022.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, announced today that new preclinical data for the companys lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Association for Cancer Research (AACR) annual meeting, to be held in New Orleans on April 8-13, 2022.
  • IL-7 is a fundamental cytokine for nave and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases).
  • In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors

Retrieved on: 
Wednesday, March 9, 2022
Heart, AACR, OSE, Clinical trial, Epitope, Large-cell lung carcinoma, B cell, IND, Immune system, ISIN, Partnership, Chemokine, Tissue, Ulcerative colitis, Macrophage, Tumor microenvironment, Myelocyte, Degenerative disease, Mab, GLOBE, CD8, Boehringer Ingelheim, Patient, IL-7, Neoplasm, Fortification, Autoimmune disease, Phagocytosis, COVID-19, Pancreatic cancer, Inflammation, PD-1, Immunotherapy, Nivolumab, Cancer, Transplant, Pharmaceutical industry, Medical imaging, Vaccine

NANTES, France, March 09, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced that early biomarker analyses from the ongoing Phase 1 clinical trial with SIRPα inhibitor BI 765063 in patients with advanced solid tumors have been selected for presentation (1) in an in-person poster session at the American Association Cancer for Research (AACR) annual meeting to be held on April 8 – 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • The goal of the biomarker analyses from the Phase 1 trial with first-in-class SIRP inhibitor BI 765063 was to characterize the impact of the product on peripheral blood immune cells (PBMCs), as well as on the tumor microenvironment.
  • These new data confirm preclinical results showing that T lymphocytes initially blocked at the tumors margin could penetrate efficiently into the tumor when blocking SIRP in parallel.
  • The Phase 1 clinical trial with BI 765063 is being conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to BI 765063.
  • BI 765063 (OSE-172, anti-SIRP mAb on CD47/SIRP pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination with ezabenlimab (PD-1 antagonist); ongoing expansion Phase 1.

OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors

Retrieved on: 
Friday, February 18, 2022
ACT, Fortification, Epitope, Patient, Autoimmune disease, Tissue, Ulcerative colitis, Company, Nivolumab, Inflammation, ISIN, Immunotherapy, Cancer, Immune system, Bluebird bio, IND, Infection, Mab, Clinical trial, Large-cell lung carcinoma, Leadership, OSE, Pancreatic cancer, Novartis, Boehringer Ingelheim, Institute, Sanofi, Director, Ipsen, Transplant, Board, IL-7, Partnership, PD-1, Growth, Research, Degenerative disease, COVID-19, Nomination, Mnemos EP, GLOBE, Drug development, Pharmaceutical industry, Fine chemical, Vaccine

NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the Company*.

Key Points: 
  • NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the Company*.
  • Most recently, Alexandre Lebeaut served as Executive Vice-President R&D and Chief Scientific Officer at Ipsen in the US.
  • Alexandre Lebeaut added: I am honored to be joining OSEs Board and I thank the Directors for their confidence.
  • On proposal from the Nomination and Remuneration Committee, the Board of Directors unanimously co-opted Alexandre Lebeaut as an independent Director.

OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104

Retrieved on: 
Thursday, February 17, 2022
Fortification, Epitope, Patient, Autoimmune disease, CEO, Tissue, Immunosuppression, Ulcerative colitis, Nivolumab, Inflammation, CD28, ISIN, Immunotherapy, Review, Solution, Cancer, Health care, Immune system, Mab, IND, Dialysis, Asahi Kasei, Clinical trial, Large-cell lung carcinoma, Safety, OSE, Pancreatic cancer, IV, Therapy, Boehringer Ingelheim, FDA, Transplant, IL-7, Partnership, Ammonia, Pharmacokinetics, PD-1, Â, COVID-19, Degenerative disease, Mnemos EP, Life, GLOBE, Pharmaceutical industry, Vaccine, Dentistry, Regulatory T cell, Veloxis Pharmaceuticals

We are very pleased with the FDA fast-track designation granted to VEL-101/FR104.

Key Points: 
  • We are very pleased with the FDA fast-track designation granted to VEL-101/FR104.
  • VEL-101, a pegylated monoclonal antibody fragment CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal.
  • VEL-101, also known as FR104, was licensed by Veloxis Pharmaceuticals, Inc. from OSE Immunotherapeutics in April 2021.
  • As part of the license agreement, Veloxis Pharmaceuticals, Inc. obtained worldwide rights to develop, manufacture, and commercialize VEL-101 for all transplant indications.

NeoImmuneTech to Present at Upcoming Business Conferences

Retrieved on: 
Wednesday, February 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, List of life sciences, Industry, NIT, GSK, PricewaterhouseCoopers, Conference, Eli Lilly, Company, Cancer, BMS, Infection, Amgen, KOSDAQ, IL-7, CA, House, Novartis, Fierce, BIO, Immunity, MBA, Pharmaceutical industry, Pfizer

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.
  • Subsequently, he will join a panel discussion titled Getting your House in Order: Strategies for Sellers to Best Prepare for a Diligence Review.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
  • The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the Company) that are based on its beliefs and expectations about the future.

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

Retrieved on: 
Monday, February 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Industry, Skin Cancer Foundation, Skin, NIT, GSK, PricewaterhouseCoopers, Eli Lilly, Recurrence, Skin cancer, MCC, Melanoma, Company, Cancer, Hoffmann-La Roche, Clinical trial, BMS, Infection, Amgen, KOSDAQ, IL-7, Patient, Roche, Safety, Squamous cell carcinoma, Novartis, CEO, CSCC, Immunity, Pharmaceutical industry, Pfizer, Genentech, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

All three of these skin cancers can grow rapidly and have the potential to be fatal if left untreated.

Key Points: 
  • All three of these skin cancers can grow rapidly and have the potential to be fatal if left untreated.
  • Melanoma and MCC are less common forms of skin cancer, but they are notable for spreading rapidly and carrying a high risk for recurrence.
  • Skin cancer is the most common form of cancer in the U.S., accounting for more diagnoses than all other cancers combined1.
  • This open-label, multicenter Phase 2a study will evaluate the safety, tolerability and anti-tumor effect of the combination therapy.